Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.46 USD | +0.69% | -2.01% | -6.41% |
25/04 | Compass Therapeutics Gets FDA Fast-Track Designation for Biliary Tract Cancer Treatment | MT |
25/04 | Compass Therapeutics Gets FDA Fast-Track for Cancer Treatment | DJ |
Sales 2024 * | - | Sales 2025 * | 11.19M 933M | Capitalization | 200M 16.64B |
---|---|---|---|---|---|
Net income 2024 * | -66M -5.5B | Net income 2025 * | -79M -6.59B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 17.8 x |
P/E ratio 2024 * |
-2.99
x | P/E ratio 2025 * |
-2.88
x | Employees | 32 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.56% |
1 day | +1.38% | ||
1 week | -2.01% | ||
Current month | -26.26% | ||
1 month | -20.65% | ||
3 months | +1.39% | ||
6 months | -17.51% | ||
Current year | -6.41% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 53 | 01/17/01 | |
Thomas Schuetz
FOU | Founder | 63 | 01/14/01 |
Neil Lerner
DFI | Director of Finance/CFO | 56 | 01/20/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Richard Lindahl
BRD | Director/Board Member | 70 | 21/23/21 |
Mary Gray
BRD | Director/Board Member | 71 | 25/22/25 |
Ellen Chiniara
BRD | Director/Board Member | 65 | 25/22/25 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.02% | 2 M€ | -.--% | ||
0.00% | 34 M€ | +2.57% | - |
Date | Price | Change | Volume |
---|---|---|---|
29/24/29 | 1.46 | +0.69% | 41 947 |
26/24/26 | 1.45 | -2.03% | 65,666 |
25/24/25 | 1.48 | 0.00% | 468,630 |
24/24/24 | 1.48 | -2.63% | 147,907 |
23/24/23 | 1.52 | +2.01% | 72,067 |
Delayed Quote Nasdaq, April 29, 2024 at 10:40 pm IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.41% | 200M | |
-2.41% | 103B | |
+1.74% | 95.28B | |
+1.46% | 22.15B | |
-15.68% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.01% | 16.05B | |
+5.28% | 13.68B | |
+35.00% | 12.17B |
- Stock Market
- Equities
- CMPX Stock